Bristol-Myers Squibb Company
HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
Last updated:
Abstract:
Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN.alpha., by acting on Tyk-2 to cause signal transduction inhibition. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
27 Oct 2017
Issue date:
24 Oct 2019